Managing comorbidities in idiopathic pulmonary fibrosis
Blair G Fulton,1 Christopher J Ryerson1,2 1Department of Medicine, 2Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada Abstract: Major risk factors for idiopathic pulmonary fibrosis (IPF) include older age and a history of smoking, which predispose to several pul...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-09-01
|
Series: | International Journal of General Medicine |
Online Access: | https://www.dovepress.com/managing-comorbidities-in-idiopathic-pulmonary-fibrosis-peer-reviewed-article-IJGM |
id |
doaj-da5a779fe92e40e69c18794b5cb7b366 |
---|---|
record_format |
Article |
spelling |
doaj-da5a779fe92e40e69c18794b5cb7b3662020-11-24T23:36:40ZengDove Medical PressInternational Journal of General Medicine1178-70742015-09-012015default30931823775Managing comorbidities in idiopathic pulmonary fibrosisFulton BGRyerson CJBlair G Fulton,1 Christopher J Ryerson1,2 1Department of Medicine, 2Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada Abstract: Major risk factors for idiopathic pulmonary fibrosis (IPF) include older age and a history of smoking, which predispose to several pulmonary and extra-pulmonary diseases. IPF can be associated with additional comorbidities through other mechanisms as either a cause or a consequence of these diseases. We review the literature regarding the management of common pulmonary and extra-pulmonary comorbidities, including chronic obstructive pulmonary disease, lung cancer, pulmonary hypertension, venous thromboembolism, sleep-disordered breathing, gastroesophageal reflux disease, coronary artery disease, depression and anxiety, and deconditioning. Recent studies have provided some guidance on the management of these diseases in IPF; however, most treatment recommendations are extrapolated from studies of non-IPF patients. Additional studies are required to more accurately determine the clinical features of these comorbidities in patients with IPF and to evaluate conventional treatments and management strategies that are beneficial in non-IPF populations. Keywords: interstitial lung disease, management, idiopathic pulmonary fibrosis, comorbiditieshttps://www.dovepress.com/managing-comorbidities-in-idiopathic-pulmonary-fibrosis-peer-reviewed-article-IJGM |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Fulton BG Ryerson CJ |
spellingShingle |
Fulton BG Ryerson CJ Managing comorbidities in idiopathic pulmonary fibrosis International Journal of General Medicine |
author_facet |
Fulton BG Ryerson CJ |
author_sort |
Fulton BG |
title |
Managing comorbidities in idiopathic pulmonary fibrosis |
title_short |
Managing comorbidities in idiopathic pulmonary fibrosis |
title_full |
Managing comorbidities in idiopathic pulmonary fibrosis |
title_fullStr |
Managing comorbidities in idiopathic pulmonary fibrosis |
title_full_unstemmed |
Managing comorbidities in idiopathic pulmonary fibrosis |
title_sort |
managing comorbidities in idiopathic pulmonary fibrosis |
publisher |
Dove Medical Press |
series |
International Journal of General Medicine |
issn |
1178-7074 |
publishDate |
2015-09-01 |
description |
Blair G Fulton,1 Christopher J Ryerson1,2 1Department of Medicine, 2Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada Abstract: Major risk factors for idiopathic pulmonary fibrosis (IPF) include older age and a history of smoking, which predispose to several pulmonary and extra-pulmonary diseases. IPF can be associated with additional comorbidities through other mechanisms as either a cause or a consequence of these diseases. We review the literature regarding the management of common pulmonary and extra-pulmonary comorbidities, including chronic obstructive pulmonary disease, lung cancer, pulmonary hypertension, venous thromboembolism, sleep-disordered breathing, gastroesophageal reflux disease, coronary artery disease, depression and anxiety, and deconditioning. Recent studies have provided some guidance on the management of these diseases in IPF; however, most treatment recommendations are extrapolated from studies of non-IPF patients. Additional studies are required to more accurately determine the clinical features of these comorbidities in patients with IPF and to evaluate conventional treatments and management strategies that are beneficial in non-IPF populations. Keywords: interstitial lung disease, management, idiopathic pulmonary fibrosis, comorbidities |
url |
https://www.dovepress.com/managing-comorbidities-in-idiopathic-pulmonary-fibrosis-peer-reviewed-article-IJGM |
work_keys_str_mv |
AT fultonbg managingcomorbiditiesinidiopathicpulmonaryfibrosis AT ryersoncj managingcomorbiditiesinidiopathicpulmonaryfibrosis |
_version_ |
1725522019269738496 |